Mor George Adi's Form 4 filing
Chemomab Therapeutics Ltd.CMMB · filed Nov 17, 2022
- Accession no.
- 0001178913-22-004098
- Filed
- Nov 17, 2022
- Trade date
- Oct 28, 2016-Nov 16, 2022
- Filing delay
- 2,211 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.21M. It was filed 2211 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mor George AdiCIK 0001851069 | Director, Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2018 | American Depositary Shares | AGrant or awardAcquired | +131,698 | $0.00 | $0 | 131,698 | Direct | |
| Oct 28, 2016 | American Depositary Shares | AGrant or awardAcquired | +33,725 | $0.00 | $0 | 33,725 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022.
Referenced by the price of 2 transactions in Table I.